Behçet's disease medical therapy

Jump to navigation Jump to search

Behçet's disease Microchapters


Patient Information


Historical Perspective




Differentiating Behçet's disease from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings





Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Behçet's disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Behçet's disease medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Behçet's disease medical therapy

CDC on Behçet's disease medical therapy

Behçet's disease medical therapy in the news

Blogs on Behçet's disease medical therapy</smal

Directions to Hospitals Treating Behçet's disease

Risk calculators and risk factors for Behçet's disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hamid Qazi, MD, BSc [2]


Current treatment is aimed at easing the symptoms, reducing inflammation, and controlling the immune system. Anti-TNF therapy, such as infliximab, has shown promise in treating the uveitis associated with the disease. Another Anti-TNF agent, etanercept, may be useful in patients with mainly skin and mucosal symptoms. Interferon alfa-2a, azathioprine, colchicine, thalidomide, dapsone and rebamipide are among other agents that are used alternatives.

Medical Therapy


  1. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001). "Effect of infliximab on sight-threatening panuveitis in Behçet's disease". Lancet. 358 (9278): 295–6. PMID 11498218.
  2. Sfikakis PP (2002). "Behçet's disease: a new target for anti-tumour necrosis factor treatment". Ann Rheum Dis. 61 Suppl 2: ii51–3. PMC 1766720. PMID 12379622.
  3. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S; et al. (2005). "Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study". J Rheumatol. 32 (1): 98–105. PMID 15630733.
  4. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S; et al. (2002). "Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study". Arch Dermatol. 138 (4): 467–71. PMID 11939808.
  5. Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I; et al. (2003). "Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis". Br J Ophthalmol. 87 (4): 423–31. PMC 1771623. PMID 12642304.
  6. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H (2002). "Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study". Isr Med Assoc J. 4 (11 Suppl): 928–30. PMID 12455182.
  7. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H (2001). "A double-blind trial of colchicine in Behçet's syndrome". Arthritis Rheum. 44 (11): 2686–92. PMID 11710724.
  8. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial". Ann Intern Med. 128 (6): 443–50. PMID 9499327. line feed character in |title= at position 83 (help)
  9. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y (2003). "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study". Drugs R D. 4 (1): 19–28. PMID 12568631.
  10. Sharquie KE, Najim RA, Abu-Raghif AR (2002). "Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study". J Dermatol. 29 (5): 267–79. PMID 12081158.

Template:WH Template:WS